Oncology

BioNTech appointed Guido Oelkers as its new CEO, replacing Ugur Sahin. Oelkers, a biopharma industry veteran, will lead the company's shift toward oncology and aim for multiple approved medicines by 2030. Sahin and cofounder Özlem Türeci are leaving to launch a new biotech focused on mRNA medicines.

GSK CEO Luke Miels announced a three-year cost-cutting plan targeting 1.9 billion pounds in annual savings by 2029, with funds reinvested into late-stage drug trials. The company aims to increase Phase 3 trials from 10 to 20 this year, focusing on areas like oncology, liver disease, vaccines, and HIV.

Bristol Myers Squibb is assembling the largest NVIDIA AI supercomputer in the life sciences industry, following a trend among pharma companies. The company expanded its computing power to develop foundation models for drug candidate interactions in areas like oncology and neurodegeneration.

GSK acquired Nuvalent, a cancer drug developer, in a $10.6 billion deal to expand its oncology portfolio, while Merck and Gilead Sciences reported success in final-stage trials for a once-weekly HIV pill combining their experimental drugs. The GSK acquisition highlights ongoing biopharma industry consolidation as companies bolster pipelines amid generic competition.

British drugmaker GSK, led by new CEO Luke Miels, has agreed to acquire US-based cancer treatment firm Nuvalent for $10.6 billion. The deal aims to strengthen GSK's oncology portfolio, with Nuvalent developing three late-stage lung cancer medications.

British drugmaker GSK has agreed to acquire US-based cancer treatment company Nuvalent for $10.6 billion to expand its oncology portfolio. The deal includes Nuvalent's three late-stage lung cancer medications.

GSK agreed to acquire Nuvalent, a cancer-focused biotech company, for $10.6 billion in a cash deal. The transaction includes a 26% premium over Nuvalent’s 30-day average share price, with GSK paying $124 per share and spending approximately $9.4 billion in cash.

A combination of Tango Therapeutics' vopimetostat and Revolution Medicines' daraxonrasib showed durable responses in most pancreatic cancer patients in an early-stage trial. Revolution's drug has demonstrated unprecedented outcomes, highlighting potential in oncology treatments.

A successful late-stage treatment for pancreatic cancer that nearly doubles patient survival rates caused doctors and global oncology professionals to stand and cheer during its announcement. The treatment marks a historic advancement in addressing the deadly disease.

A new study suggests that weight loss injections may have additional benefits beyond weight reduction, potentially helping to prevent cancer from spreading. The research indicates these medications could play a role in cancer treatment strategies alongside traditional therapies.

Tumor cells develop drug resistance through a genetic mechanism, but researchers suggest this same strategy could be exploited to combat cancer. The discovery highlights a potential dual-use approach for overcoming treatment challenges.